Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-03T23:23:27.283Z.
Calculation as of: 2026-10-03T23:23:27.283Z.
Quote observation: 2026-10-02T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4505e98710625341619211ab55aeba527b7a9ae851bd18a42260ddbfed9e8a0e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$13.98B
EBITDA Yield
4.71%
TTM Avg
5.80%
3Y Avg
6.25%
5Y Avg
6.15%
Market Cap
$12.41B
EBITDA Yield
9.44%
TTM Avg
9.63%
3Y Avg
7.98%
5Y Avg
6.68%
Market Cap
$12.14B
EBITDA Yield
3.45%
TTM Avg
4.27%
3Y Avg
4.90%
5Y Avg
5.03%
Market Cap
$11.88B
EBITDA Yield
10.01%
TTM Avg
10.03%
3Y Avg
12.08%
5Y Avg
11.93%
Market Cap
$15.21B
EBITDA Yield
14.16%
TTM Avg
12.27%
3Y Avg
10.66%
5Y Avg
10.66%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tempus AI, Inc. (TEM) | $13.43B | N/A | N/A | N/A | N/A |
| Charles River Laboratories International, Inc. (CRL)vs › | $13.98B | 4.71% | 5.80% | 6.25% | 6.15% |
| Penumbra, Inc. (PEN)vs › | $12.51B | 1.63% | 1.61% | 1.04% | 0.84% |
| ICON Public Limited Company (ICLR)vs › | $12.41B | 9.44% | 9.63% | 7.98% | 6.68% |
| Exelixis, Inc. (EXEL)vs › | $14.68B | 6.87% | 7.06% | 5.23% | 5.09% |
| Baxter International Inc. (BAX)vs › | $12.14B | 3.45% | 4.27% | 4.90% | 5.03% |
| Encompass Health Corporation (EHC)vs › | $11.88B | 10.01% | 10.03% | 12.08% | 11.93% |
| Solventum Corporation (SOLV)vs › | $15.21B | 14.16% | 12.27% | 10.66% | 10.66% |
| DaVita Inc. (DVA)vs › | $11.47B | 13.06% | 11.31% | 11.13% | 11.02% |
| Bio-Techne Corporation (TECH)vs › | $11.34B | 3.07% | 2.49% | 2.89% | 2.79% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
